Mannitol Dry Powder (Bronchitol®)

Assessment Status Assessment Process Complete
Drug Mannitol Dry Powder
Brand Bronchitol®
Indication Mannitol dry powder for inhalation for the treatment of cystic fibrosis (CF)
Assessment Process
Rapid review commissioned 11/09/2012
Rapid review completed 21/09/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 14/03/2014
NCPE assessment completed 29/08/2014
NCPE assessment outcome Reimbursement not recommended

Technical Summary 2014

Assessment Status Rapid Review Complete
Rapid review received 02/04/2019
Rapid review completed 29/04/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Mannitol Dry Powder (Bronchitol®) not be considered for reimbursement.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.